23andMe to Present Data on Two Clinical Stage Immuno-Oncology Programs at the American Association for Cancer Research (AACR) Annual Meeting 2024 - Seite 2

Key Takeaways:

• CD200R1 is a dominant immune checkpoint and differentiated from PD-1, based on both the pattern of expression on tumor infiltrating immune cells from patient tumors and the pattern of activation on patient peripheral mononuclear blood cells.
• 23andMe preclinical results support the potential for 23ME-00610 to combine with anti-PD-1 and antiangiogenics.

Key Details:

• Prevalence of CD200R1 and its ligand CD200 was characterized on tumor samples from patients with clear cell renal cell and serous ovarian carcinomas.
• CD200R1 is broadly expressed on tumor-infiltrating immune cells, including T cells and NK cells, whereas expression of PD-1 is predominantly restricted to T cells.
• 23ME-00610 differentially enhanced interferon-gamma secretion from cancer patient peripheral blood mononuclear cells relative to anti-PD-1, and 23ME-00610 enhanced both T and NK cell anti-tumor activity.
• CD200/R1 is an independent immunosuppressive pathway from PD/L-1, with potential for synergism in patients with cancer based on preclinical combination data with primary human T cells.
• CD200, the ligand of CD200R1, is expressed on both tumor cells and endothelial cells, and combination anti-CD200 with anti-VEGF led to tumor growth inhibition relative to single agents in a preclinical mouse model.
• 23ME-00610 is currently in the Phase 2a portion of a Phase 1/2a clinical trial (NCT05199272).

The presentations will be available on the 23andMe Investor Relations and Therapeutics websites on April 8, 2024.

Presentation details - 23ME-01473:

Oral presentation

• Title: Discovery of ULBP6 as a novel immuno-oncology target using pleiotropic signals from 23andMeʼs genetic and health survey database
• Session Type: Minisymposium
• Session Category: Experimental and Molecular Therapeutics
• Session Title: Drug Discovery 1: New Targets and Approaches
• Session Date and Time: Monday, April 8, 2024, 3:20-3:35 PM PT
• Location: Room 30, Upper Level of the San Diego Convention Center
• Published Abstract Number: 3903
  

Poster presentation

• Title: 23ME-01473, a novel anti-ULBP6/2/5 monoclonal antibody, reinvigorates anti-tumor NK cell function through NKG2D and FcγRIIIa activation
• Session Category: Clinical Research
• Session Title: Antibodies 1
• Session Date and Time: Monday, April 8, 2024, 9:00 AM - 12:30 PM PT
• Location: Poster Section 38
• Poster Board Number: 21
• Published Abstract Number: 2375